Table 2.
Lymph node involvement and clinicopathological characteristics of pT1 IAC and SCC patients, n (%)
| Histology | IAC | P value | SCC | P value | ||
|---|---|---|---|---|---|---|
| pN0 (n = 220) | pN (+) (n = 33) | pN0 (n = 43) | pN (+) (n = 29) | |||
| Age (mean), yrs. | ||||||
| ≤60 | 90 (40.9) | 17 (51.5) | 0.263 | 11 (25.6) | 12 (41.4) | 0.201 |
| >60 | 130 (59.1) | 16 (48.5) | 32 (74.4) | 17 (58.6) | ||
| Gender | ||||||
| Male | 104 (47.3) | 15 (44.5) | 0.854 | 41 (95.3) | 27 (93.1) | 1.00 |
| Female | 116 (52.7) | 18 (54.5) | 2 (4.7) | 2 (6.9) | ||
| Tobacco smoking history | ||||||
| Never | 139 (63.2) | 20 (60.6) | 0.847 | 8 (18.6) | 5 (17.2) | 1.00 |
| Ever/current | 81 (36.8) | 13 (39.4) | 35 (81.4) | 24 (82.8) | ||
| CEA level (n = 395) | ||||||
| <5.0 IU/mL | 183 (83.2) | 14 (42.4) | <0.0001 | 33 (76.7) | 20 (69.0) | 0.587 |
| ≥5.0 IU/mL | 37 (16.8) | 19 (57.6) | 10 (23.3) | 9 (31.0) | ||
| Tumor location | ||||||
| Upper lobe | 131 (59.5) | 18 (54.6) | 0.145 | 23 (53.5) | 14 (48.3) | 0.760 |
| Middle lobe | 17 (7.7) | 3 (9.1) | 1 (2.3) | 2 (6.9) | ||
| Lower lobe | 72 (32.7) | 11 (33.3) | 15 (34.9) | 9 (31.0) | ||
| Middle-lower lobe | 0 | 1 (3.0) | 4 (9.3) | 4 (13.8) | ||
| Type of surgery | ||||||
| Lobectomy | 197 (89.5) | 27 (81.8) | 0.236 | 38 (88.4) | 26 (89.7) | 0.591 |
| Limited resection | 23 (10.5) | 6 (18.2) | 5 (11.6) | 3 (10.3) | ||
| Adjuvant chemotherapy | ||||||
| No | 146 (66.4) | 0 | <0.0001 | 20 (46.5) | 0 | <0.0001 |
| Yes | 74 (33.6) | 33 (100.0) | 23 (53.5) | 29 (100.0) | ||
| Tumor size, cm | ||||||
| ≤1.0 | 27 (12.3) | 0 | 0.015 | 1 (2.3) | 0 | 1.00 |
| 1.0–≤2.0 | 136 (61.8) | 18 (54.5) | 17 (39.5) | 11 (37.9) | ||
| 2.0–≤3.0 | 57 (25.9) | 15 (45.5) | 25 (58.2) | 18 (62.1) | ||
CEA carcinoembryonic antigen, IAC invasive lung adenocarcinoma, SCC squamous cell lung cancer